Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility [Seeking Alpha]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Seeking Alpha
Play 20min Summary Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and Dermavant have bolstered Roivant's cash reserves. Key potential catalysts include Immunovant's batoclimab in Phase 3 trials and namilumab in a Phase 2 trial, though drug candidate performance remains a critical risk factor. Litigation against Moderna and Pfizer, coupled with Techbio advancements, could drive future valuation. Dragos Condrea/iStock via Getty Images Investment Thesis Roivant Sciences Ltd.'s ( NASDAQ: ROIV ) high valuation, in my opinion, is the result of a beautiful story combining traditional drug development, partnerships a promising portfolio, Techbio AI, revenues, and cash. After the sale of This article was written by Tejo Strategy Investing Follower s Follow I am a long-term investor focused on growth markets, AI and biotech oppor
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- U.S. can become a crypto superpower with 'sensible' regulation, Eric Trump says [MSNBC.com]MSNBC.com
- U.S. can become a crypto superpower with ‘sensible' regulation, Eric Trump says [CNBC]CNBC
- Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary SarcoidosisGlobeNewswire
- Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary SarcoidosisGlobeNewswire
- Everything to know about Vivek Ramaswamy, co-lead of the Department of Government Efficiency with Elon Musk [Business Insider]Business Insider
ROIV
Earnings
- 11/12/24 - Miss
ROIV
Analyst Actions
- 11/13/24 - HC Wainwright
ROIV
Sec Filings
- 12/20/24 - Form 4
- 12/20/24 - Form 144
- 12/18/24 - Form 144
- ROIV's page on the SEC website